INVO Fertility reports 23% Q1 2026 revenue growth and strengthened balance sheet

INVO Fertility achieved $2.0 million in Q1 2026 revenue, up 23% year-over-year, while eliminating all Series C-2 Preferred Stock and warrant liabilities to improve its capital structure. The company's stockholders' equity nearly doubled to $15.0 million, demonstrating financial stabilization amid continued clinic expansion and acquisition integration.